The Investor Relations website contains information about Heron Therapeutics's business for stockholders, potential investors, and financial analysts.

CorMedix Therapeutics will acquire substantially all assets of Heron Therapeutics, adding four hospital and acute-care products to its portfolio. The upfront price is $145 million in cash plus 14,583,333 CorMedix shares, worth about $77.6 million at the November 6 closing price. Heron could also earn up to $55 million tied to 2028 net sales of its ZYNRELEF pain drug, plus a 5% royalty on certain product sales above a threshold. The other products are APONVIE, CINVANTI, and SUSTOL. CorMedix expects the deal to add to earnings and free cash flow right away, and to deliver $45-$60 million in operating cost savings. It will draw $75 million from a new term loan with funds managed by Pharmakon Advisors. The deal is expected to close in the first quarter of 2027, subject to regulatory clearance and Heron stockholder approval.

Biotech movers november 9, 2026: ZURA -70% after Phase 2 TibuSHIELD miss; MODD +39% on Pivot market research. BPC UPDATE 11/09/2026 ET TL;DR - biotech movers: november 9, 2026. * Zura Bio (ZURA): Phase 2 TibuSHIELD missed its primary and key secondary endpoints in hidradenitis suppurativa; Zura is discontinuing development in the indication. * Onconetix (ONCO): Revised its Realbotix merger, extending the outside date to March 31, 2027, eliminating the minimum-cash condition and advancing $3M to Realbotix. * Faeth Therapeutics (FTH): Phase 2 PIK-201 showed a 33% confirmed ORR and 83% disease-control rate with PIKTOR plus paclitaxel in advanced endometrial cancer. * Abeona Therapeutics (ABEO): Acquired Phase 3-ready ABO-801 for $20M in stock and raised a $30M PIPE, with a redesigned EoE Phase 3 trial planned for mid-2027. * Modular Medical (MODD): Market research showed strong stated interest in its Pivot tubeless insulin pump, though the findings do not yet demonstrate adoption or revenue traction. * Delcath Systems (DCTH): Q3 revenue surged 70% to $35.1M, driven by $32.7M in HEPZATO sales, prompting higher 2026 revenue guidance. * Janux Therapeutics (JANX): Preliminary healthy-volunteer data showed >90% B-cell depletion at 3 mg with JANX011 and only Grade 1 CRS, ahead of planned 2027 patient trials. * Heron Therapeutics (HRTX): Q3 revenue declined 7.8% to $35.3M, while investor focus remains centered on the pending sale of substantially all assets to CorMedix. Biotech updates. Modular Medical (NASDAQ: MODD) reported patient market research showing strong interest in its Pivot tubeless patch pump, with 90% of MDI users open to simpler insulin delivery and 82.8% of high-burden participants willing to discuss Pivot with a provider. The findings support commercial positioning ahead of full launch, but are market-research data rather than evidence of actual adoption, reimbursement or revenue traction. Shares closed up 39% at $1.85. Delcath Systems (NASDAQ: DCTH) announced third-quarter total revenue reached $35.1 million, reflecting a 70% year-over-year increase driven by $32.7 million in HEPZATO net product sales. The company achieved an 89% gross margin alongside net income of $7.0 million and adjusted EBITDA of $11.5 million. Management raised full-year 2026 revenue guidance to 115-117 million, citing sustained commercial momentum for HEPZATO, positive cash flow generation, and a balance sheet free of debt to fund ongoing clinical development. Shares closed up 36% at $20.27. Heron Therapeutics (NASDAQ: HRTX) posted third-quarter revenue of $35.3 million, marking a 7.8% decrease year-over-year. While Acute Care sales grew 22.5%, this gain was offset by a 22.2% drop in Oncology Supportive Care revenue. The primary catalyst remains CorMedix's definitive agreement to purchase nearly all of Heron's assets, moving market attention from independent operational metrics to deal details, stockholder authorization, and final transaction completion. Shares closed up 26% at $0.37. Zura Bio (NASDAQ: ZURA) disclosed top-line results from its Phase 2 TibuSHIELD trial evaluating tibulizumab in hidradenitis suppurativa, noting that the study failed to meet its primary and key secondary endpoints due to minimal separation from placebo. Reductions in abscess and inflammatory nodule counts at 16 weeks were 56.0% and 58.1% across treatment groups versus 52.5% for placebo, while HiSCR50 and HiSCR75 response rates showed no statistically significant differences. Despite an overall tolerable safety profile, Zura has decided to discontinue development of tibulizumab for hidradenitis suppurativa to reallocate resources toward programs in systemic sclerosis and polymyalgia rheumatica, with the next clinical readout targeted for 1H 2027. Shares closed down 70% at $1.24. Onconetix (NASDAQ: ONCO) and Realbotix revised their all-stock merger terms, extending the outside transaction date to March 31, 2027, and eliminating the minimum net cash requirement at closing. Additionally, ONCO provided Realbotix with $3 million in advanced funds. While the adjustments grant procedural flexibility and preserve the Nasdaq listing pathway, they highlight transaction delays and diminish balance-sheet safeguards for ONCO shareholders prior to deal completion. Shares closed down 48% at $3.58. Faeth Therapeutics (NASDAQ: FTH) reported positive top-line results from the Phase 2 PIK-201 trial assessing PIKTOR in combination with paclitaxel for advanced endometrial cancer. The study demonstrated a confirmed 33% overall response rate (12/36) and an 83% disease control rate, which rose to a 44% response rate in patients harboring PIK3CA mutations. Median progression-free survival was estimated at 7.4 months, with a 6-month PFS rate of 62%. Severe treatment-emergent adverse events (Grade 3 or higher) occurred in 64% of subjects, though toxicity led to treatment discontinuation in only 5%. Following upcoming regulatory discussions, these single-arm findings support plans to advance the combination into a pivotal Phase 3 study. Shares closed down 42% at $12.68. Janux Therapeutics (NASDAQ: JANX) disclosed preliminary Phase 1 healthy-volunteer findings for JANX011, demonstrating exceeding 90% B-cell depletion among most subjects at the 3 mg dose level that persisted through Day 42. Treatment-emergent side effects were limited to Grade 1 cytokine release syndrome, with zero serious adverse events or dose-limiting toxicities recorded. Although these results offer initial human proof-of-concept for the ARM technology and pave the way for planned Phase 2 trials in immune thrombocytopenia and rheumatoid arthritis starting in 1H 2027, therapeutic efficacy in target patient populations has yet to be demonstrated. Shares closed down 28% at $12.76. Abeona Therapeutics (NASDAQ: ABEO) secured Phase 3-ready ABO-801 for eosinophilic esophagitis via a $20 million all-stock acquisition requiring zero upfront cash, alongside a $30 million PIPE financing intended to advance clinical progress and support ZEVASKYN commercialization. While the transaction expands Abeona's portfolio, the asset introduces operational risk given that two previous Phase 3 trials failed to satisfy their prespecified primary efficacy metrics; management plans to initiate a redesigned Phase 3 program in mid-2027. Shares closed down 39% at $2.54.